«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

29卷

期数:

2023年06期

页码:

609-616

栏目:

基础医学

出版日期:

2023-11-20

文章信息/Info

Title:

Screening of key genes in polycystic ovary syndrome and analysis of their correlation with disease progression and prognosis

文章编号:

1006-8147(2023) 06-0609-08

作者:

孙奎奎¹; 杨微微²; 王文靖²; 郝颖新²; 郭波²; 任晨春²; 鞠明艳²

（1.天津医科大学研究生院，天津300070；2.天津市中心妇产科医院检验科，天津 300100）

Author(s):

SUN Kui-kui¹; YANG Wei-wei²; WANG Wen-jing²; HAO Ying-xin²; GUO Bo²; REN Chen-chun²; JU Ming-yan²

（1. School of Gradute，Tianjin Medical University，Tianjin 300070，China; 2. Department of Clinical Laboratory，Tianjin Central Hospital of Obstetrics and Gynecology，Tianjin 300100，China）

关键词:

多囊卵巢综合征; 生物信息学分析; ITGAM; HMOX1

Keywords:

polycystic ovary syndrome; bioinformatic analysis; ITGAM; HMOX1

分类号:

R711

DOI:

-

文献标志码:

A

摘要:

目的：通过生物信息学方法筛选多囊卵巢综合征（PCOS）的关键基因并分析其与PCOS进展和预后的相关性。方法：在GEO数据库中下载GSE34526数据集的表达谱，利用R软件筛选数据集中PCOS患者卵巢颗粒细胞（n=7）和正常颗粒细胞（n=3）的差异表达基因（DEGs），对DEGs进行基因本体论（GO）和京都百科全书基因和基因组（KEGG）富集分析，识别关键基因。使用单样本基因富集分析（ssGSEA）评分量化每个PCOS样本中的免疫信号的富集水平，进行抗肿瘤免疫和促肿瘤抑制评分。利用人类蛋白质图谱数据库（HPA）分析关键基因在卵巢癌（OC）、乳腺癌（BRCA）和子宫内膜癌（UCEC）中的蛋白表达水平，绘制ROC曲线分析3年、5年和10年癌症生存率。结果：本研究共筛选出16个DEGs，GO和KEGG分析结果显示DEGs在PCOS患者的细胞黏附分子（CAMs）、补体和凝血级联、上皮细胞迁移和炎症反应的正向调控等通路中富集，进一步筛选出2个关键基因，ITGAM和HMOX1。二者与促炎免疫细胞（如巨噬细胞、MDSCs、中性粒细胞、浆细胞样树突状细胞、调节性T细胞）的相关性分析显示，ITGAM（P分别为0.001、< 0.001、0.051、0.04、< 0.001）和HMOX1（P分别为< 0.001、0.001、< 0.001、< 0.001、0.001）与以上促炎免疫细胞呈正相关，即发挥促炎作用。在OC、BRCA和UCEC组织中，ITGAM和HMOX1蛋白水平较高，而对照组无表达。作为不良预后因素，ITGAM显著影响PCOS继发的OC患者的生存（P=0.004 6），ITGAM在OC中3、5、10年生存预测率ROC曲线下面积（AUC）均>0.5，其中10年AUC >0.59。HMOX1在BRCA、OC和UCEC中的3年AUC > 0.5，在BRCA中的10年AUC > 0.6，均有较好的预测效能。ITGAM+HMOX1联合预测在BRCA中的3、5、10年AUC分别为0.51、0.498、0.606，在OC中分别为0.563、0.537、0.481，在UCEC中分别为0.556、0.479、0.472。结论：ITGAM和HMOX1可以作为PCOS的潜在诊断和治疗靶点，其表达水平可以评价PCOS病情发展及预后。

Abstract:

Objective： To screen key genes of polycystic ovary syndrome （PCOS） using bioinformatic analysis，and to explore their predictive effects on the progression and prognosis of PCOS. Methods：The expression profile of the GSE34526 dataset was downloaded from the GEO database，and the differential expression genes（DEGs） of ovarian granulosa cells （n=7） and normal granulosa cells （n=3） of PCOS patients in the dataset were screened using R software. Genetic Ontological（GO） and Kyoto Encyclopedia Gene and Genome（KEGG） enrichment analyses were performed on DEGs to identify key genes. A single-sample geneset enrichment analysis （ssGSEA） score was used to quantify the level of immune signal enrichment in each PCOS sample to perform anti-tumor immunity and pro-tumor inhibition scores. The Human Protein Profile Database（HPA） was used to analyze the protein expression levels of key genes in ovarian cancer（OC），breast cancer （BRCA） and uterine corpus endometrial cancer（UCEC）. ROC curves were plotted to analyze the 3-year，5-year and 10-year cancer survival rates. Results：In this study，a total of 16 DEGs were screened. The results of GO and KEGG analysis showed that DEGs was enriched in the pathways of cell adhesion molecules（CAMs），complement and coagulation cascade，epithelial cell migration and positive regulation of inflammatory response in PCOS patients. Two key genes，ITGAM and HMOX1，were further screened. Correlation analysis between the two genes and pro-inflammatory immune cells （such as macrophages，MDSCs，neutrophils，plasmacytoid dendritic cells，regulatory T cells） showed that ITGAM （P values 0.001，< 0.001，0.051，0.04，< 0.001，respectively） and HMOX1（P values < 0.001，0.001，< 0.001， <0.001，<0.001，0.001，respectively） were positively correlated with the above pro-inflammatory immune cells，that was，they played a pro-inflammatory role. The levels of ITGAM and HMOX1 proteins were higher in OC，BRCA and UCEC tissues，but not in the control. As an adverse prognostic factor，ITGAM significantly affected the survival of OC patients secondary to PCOS （P=0.0046）. The area under ROC curve（AUC） of ITGAM in OC with 3-，5- and 10-year survival prediction rates were> 0.5，and the AUC at 10-year was > 0.59. The 3-year AUC of HMOX1 in BRCA，OC and UCEC were> 0.5，and the 10-year AUC in BRCA were> 0.6，which showed good predictive efficiency. The combined ITGAM+HMOX1 forecast for the 3-year，5-year and 10-year AUC in BRCA were 0.51，0.498 and 0.606，respectively. In OC，the values were 0.563，0.537 and 0.481，respectively. In UCEC，they were 0.556，0.479 and 0.472，respectively. Conclusion：ITGAM and HMOX1 can be used as potential diagnostic and therapeutic targets for PCOS，and their expression levels can be used to evaluate the development and prognosis of PCOS.

参考文献/References:

[1] HOEGER K M，DOKRAS A，PILTONEN T. Update on PCOS：consequences，challenges，and guiding treatment [J]. J Clin Endocrinol Metab，2021，106（3）：1071-1083.
[2] LIZNEVA D，KIRUBAKARAN R，MYKHALCHENKO K，et al. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations：systematic review and meta-analysis [J]. Fertil Steril，2016，106（6）：1510-1520.
[3] COONEY L G，DOKRAS A. Beyond fertility：polycystic ovary syndrome and long-term health [J]. Fertil Steril，2018，110（5）：794-809.
[4] SCHINDLER A E. Progestational effects of dydrogesterone in vitro，in vivo and on the human endometrium[J]. Maturitas，2009，65（Suppl 1）：S3-S11.
[5] MORGANTE G，MASSARO M G，DI SABATINO A，et al. Therapeutic approach for metabolic disorders and infertility in women with PCOS [J]. Gynecol Endocrinol，2018，34（1）：4-9.
[6] MARCH W A，MOORE V M，WILLSON K J，et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria [J]. Hum Reprod，2010，25（2）：544-551.
[7] BARRETT T，WILHITE S E，LEDOUX P，et al. NCBI GEO：archive for functional genomics data sets-update [J]. Nucleic Acids Res，2013，41（Database issue）：991-995.
[8] TOMCZAK K，CZERWINSKA P，WIZNEROWICZ M. The Cancer Genome Atlas（TCGA）：an immeasurable source of knowledge [J]. Contemp Oncol （Pozn），2015，19（1A）：68-77.
[9] RITCHIE ME，PHIPSON B，WU D，et al. limma powers differential expression analyses for RNA-sequencing and microarray studies [J]. Nucleic Acids Res，2015，43（7）：e47.
[10] YU G，WANG L G，HAN Y，et al. clusterProfiler：an R package for comparing biological themes among gene clusters [J]. OMICS，2012， 16（5）：284-287.
[11] KANEHISA M，FURUMICHI M，TANABE M，et al. KEGG：new perspectives on genomes，pathways，diseases and drugs[J]. Nucleic Acids Res，2017，45（D1）：353-361.
[12] GENE ONTOLOGY C. Gene Ontology Consortium：going forward [J]. Nucleic Acids Res，2015，43（Database issue）：1049-1056.
[13] BARBIE D A，TAMAYO P，BOEHM J S，et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 [J]. Nature，2009，462（7269）：108-112.
[14] CHAROENTONG P，FINOTELLO F，ANGELOVA M，et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade[J]. Cell Rep，2017，18（1）：248-262.
[15] PONTEN F，JIRSTROM K，UHLEN M. The Human Protein Atlas：a tool for pathology [J]. J Pathol，2008，216（4）：387-393.
[16] ZOU J，LI Y，LIAO N，et al. Identification of key genes associated with polycystic ovary syndrome（PCOS） and ovarian cancer using an integrated bioinformatics analysis [J]. J Ovarian Res，2022，15（1）：30.
[17] WANG W，JIANG Q，NIU Y，et al. Proteomics and bioinformatics analysis of follicular fluid from patients with polycystic ovary syndrome [J]. Front Mol Biosci，2022，9：956406.
[18] YAO X，WANG X. Bioinformatics searching of diagnostic markers and immune infiltration in polycystic ovary syndrome[J]. Front Genet，2022，13：937309.
[19] DULEBA A J，DOKRAS A. Is PCOS an inflammatory process? [J]. Fertil Steril，2012，97（1）：7-12.
[20] JI X，YE Y，WANG L，et al. PDE4 inhibitor Roflumilast modulates inflammation and lipid accumulation in PCOS mice to improve ovarian function and reduce DHEA-induced granulosa cell apoptosis in vitro[J]. Drug Dev Res，2023，84（2）：226-237.
[21] ZHANG Y，WANG H. Integrin signalling and function in immune cells [J]. Immunology，2012，135（4）：268-275.
[22] FAGERHOLM S C，VARIS M，STEFANIDAKIS M，et al. alpha-Chain phosphorylation of the human leukocyte CD11b/CD18 （Mac-1） integrin is pivotal for integrin activation to bind ICAMs and leukocyte extravasation [J]. Blood，2006，108（10）：3379-3386.
[23] CHIANG S K，CHEN S E，CHANG L C. A dual role of heme oxygenase-1 in cancer cells [J]. Int J Mol Sci，2018，20（1）：39.
[24] YUMICEBA V，LOPEZ-CORTES A，PEREZ-VILLA A，et al. Oncology and pharmacogenomics insights in polycystic ovary syndrome：an integrative analysis[J]. Front Endocrinol （Lausanne），2020，11：585130.
[25] ZHAO Z，XU Y，LU J，et al. High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells[J]. Clin Transl Oncol，2018， 20（4）：491-499.
[26] GOMEZ-LOMELI P，BRAVO-CUELLAR A，HERNANDEZ-FLORES G，et al. Increase of IFN-gamma and TNF-alpha production in CD107a+ NK-92 cells co-cultured with cervical cancer cell lines pre-treated with the HO-1 inhibitor[J]. Cancer Cell Int，2014，14（1）：100.
[27] SUN H L，ZHOU X，XUE Y F，et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma[J]. World J Gastroenterol，2012，18（25）：3303-3309.

相似文献/References:

[1]李 江,王 刚.性激素结合球蛋白在多囊卵巢综合征患者中的变化及与其他指标的关系[J].天津医科大学学报,2016,22(04):325.
　LI Jiang,WANG Gang.Changes of SHBG in patients with polycystic ovary syndrome and their relationship with other indicators[J].Journal of Tianjin Medical University,2016,22(06):325.
[2]李英,张学军.miR-93在多囊卵巢综合征患者血清中的表达及临床意义[J].天津医科大学学报,2018,24(03):209.
　LI Ying,ZHANG Xue-jun.Expression and clinical significance of miR-93 in the serum of patients with polycystic ovary syndrome[J].Journal of Tianjin Medical University,2018,24(06):209.
[3]刘 娇,罗海宁,韩 莹,等.比较GnRH激动剂长方案与GnRH拮抗剂方案对LH/FSH比值大于等于2的多囊卵巢综合征患者临床结局影响[J].天津医科大学学报,2019,25(04):382.
　LIU Jiao,LUO Hai-ning,HAN Ying,et al.Effects of different GnRH-analogue on polycystic ovarian syndrome with LH/FSH ratioof 2 or higher[J].Journal of Tianjin Medical University,2019,25(06):382.
[4]邹怡欣,时雨杰综 述,刘 煜,等.多囊卵巢综合征与生物钟的研究进展[J].天津医科大学学报,2020,26(01):91.
[5]刘贝贝,刘伟靓,杜曲晓,等.血清miR-27a水平与多囊卵巢综合征及其临床特征的相关性[J].天津医科大学学报,2021,27(02):117.
　LIU Bei-bei,LIU Wei-liang,DU Qu-xiao,et al.Correlation of serum miR-27a level with polycystic ovarian syndrome and its clinical characteristics[J].Journal of Tianjin Medical University,2021,27(06):117.
[6]刘玉林,臧玉琴,王颖梅,等.基于生物信息学分析筛选宫颈癌进展中的关键基因[J].天津医科大学学报,2022,28(01):8.
　LIU Yu-lin,ZANG Yu-qin,WANG Ying-mei,et al.Identification of key genes in cervical cancer progression by integrated bioinformatics analysis[J].Journal of Tianjin Medical University,2022,28(06):8.
[7]董蕾,史天云.多囊卵巢综合征外周血中miR-132和SMAD4的表达对颗粒细胞增殖和凋亡的影响[J].天津医科大学学报,2022,28(05):525.
　DONG Lei,SHI Tian-yun.Effects of miR-132 and SMAD4 expression in peripheral blood of polycystic ovary syndrome on the proliferation and apoptosis of granulosa cells[J].Journal of Tianjin Medical University,2022,28(06):525.
[8]周 彤,赵 倩.整合多组学数据筛选胰腺癌进展中的关键基因[J].天津医科大学学报,2024,30(02):132.[doi:10.20135/j.issn.1006-8147.2024.02.0132]
　ZHOU Tong,ZHAO Qian.Integrating multi-omics data to screen key genes in pancreatic cancer progression[J].Journal of Tianjin Medical University,2024,30(06):132.[doi:10.20135/j.issn.1006-8147.2024.02.0132]

备注/Memo

备注/Memo:

基金项目 天津市卫生健康委员会科技项目（ZC20117）；天津市医学重点学科（专科）建设项目（妇产科学TJYXZDXK-043A）；天津市科技计划项目（21JCQNJC01860）；天津市北辰区科技计划项目（SHGY-2022015）
作者简介 孙奎奎（1982-），女，主治医师，硕士在读，研究方向：女性不孕及围绝经期疾病的相关研究；通信作者：鞠明艳，E-mail：jumingyan@outlook.com，任晨春，E-mail：rccxqy@163.com。

常用功能

更新日期/Last Update: 2023-12-01